Cargando…
Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
BACKGROUND: Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is limited and unsatisfactory. METHODS: Chinese BTC patients receiving a PD-1 inhibitor with chemotherapy, PD-1 inhibitor monotherapy or chemotherapy alone were retrospectively analyzed. The primary outcome was over...
Autores principales: | Sun, Danyang, Ma, Junxun, Wang, Jinliang, Han, Chun, Qian, Yuanyu, Chen, Guangying, Li, Xiaoyan, Zhang, Juan, Cui, Pengfei, Du, Wushuang, Wu, Zhaozhen, Chen, Shixue, Zheng, Xuan, Yue, Zhichao, Song, Jia, Gao, Chan, Zhao, Xiaochen, Cai, Shangli, Hu, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768892/ https://www.ncbi.nlm.nih.gov/pubmed/31535160 http://dx.doi.org/10.1007/s00262-019-02386-w |
Ejemplares similares
-
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
por: Chen, Shixue, et al.
Publicado: (2021) -
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020) -
Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
por: Sun, Danyang, et al.
Publicado: (2018) -
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021) -
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
por: Wu, Zhaozhen, et al.
Publicado: (2021)